NO-vermittelte Effekte der Aminosäure L-Arginin auf die  TGF-ß-Überexpression im Modell der akuten Anti-Thy-1-GlomerulonephritisUte Daig1121.11.231.2.11.2.21.2.341.2.41.2.4.11.2.4.251.2.4.361.3781.49292.12.2102.2.12.2.22.2.3112.2.42.3122.3.12.3.1.12.3.1.2132.3.1.32.3.214152.42.4.12.4.216172.52.5.12.5.22.5.3182.5.42.5.52.6192.6.12.6.1.12.6.1.22.6.1.2.1202.6.1.2.22.6.1.32.6.2212.6.2.12.6.2.22.6.2.3222.6.3405#402.6.42.6.4.1232.6.4.22.6.4.2.12.6.524190#492.6.6252.6.6.12.6.6.2262.7272.82.93273.13.1.128566#1633.1.23.1.2.12930586#4393.1.2.23.1.2.33.1.331586#4393.1.432566#4253.1.5586#4393.1.633586#4393.1.734586#4393.1.835566#4253.1.93.1.9.136586#4393.1.9.2586#4393.1.9.337586#4393.1.1038586#4393.1.11566#4253.1.12393.1.12.1586#4393.1.12.240566#4253.1.1341585#6373.23.2.13.2.2423.2.2.1586#4393.2.2.2433.2.2.33.2.344586#4263.2.4586#4393.2.545586#4263.2.646586#4393.2.7566#4253.2.7.147586#4393.2.7.248586#4393.3494494.14.1.1504.1.2514.1.34.24.34.3.1524.3.2534.3.3544.44.5554.64.75655758 6. Literaturverzeichnis 7. Erklärung an Eides Statt 8. Publikationsverzeichnis DanksagungdeInhaltsverzeichnisHilfe 6. Literaturverzeichnis 1 Klahr S, Schreiner G, Ichikawa I : The progression of renal disease. N Engl J Med. 1988, 318, S.1657-1666, 2 Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994, 331, S.1286-1292, 3 Reyes AA, Purkerson ML, Karl I, Klahr S: Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kid Dis. 1992, 20, S.168-176, 4 Katoh T, Takahashi K, Klahr S, Reyes AA, Badr KF: L-arginine decreases the infiltration of the kidney by macrophages in obstructive nephropathy and puromycin-induced nephrosis. Kidney Int. 1994, 45, S.1346-1354, 5 Reyes AA, Karl IE, Kissane J, Klahr S: L-arginine administration prevents glomerular hyperfiltration and decreases proteinuria in diabetic rats. J Am Soc Nephrol. 1993, 4, S.1039-1045, 6 Andrade L, Campos SB, Seguro AC: Hypercholesterolemia aggravates radiocontrast nephrotxicity: protective role of L-arginine. Kidney Int. 1998, 53 (6), S.1736-1742, 7 Reckelhoff JF, Kellum JA, Jr., Racusen LC, Hildebrandt DA: Long-term dietary supplementation with L-arginine prevents age-related reduction in renal function. Am J Physiol. 1997, 272, S.R1768-1774, 8 Bohle A: Die Bedeutung des Niereninterstitiums für die Nierenfunktion. Klin Wochenschr. 1982, 60, S.1186-1190, 9 Peters H, Border WA, Noble NA: Angiotensin I und L-arginine in tissue fibrosis: more than blood pressure. Kid Int. 1997, 51, S.1481-1486, 10 Peters H, Border WA, Noble NA: From rats to men: A perspective on dietary L-arginine supplementation in human renal disease. Nephrol Dial Transplant. 1999, 14, S.1640-1660, 11 Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group11. N Eng J Med. 1994, 330, S.877-884,

12 Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study. N Engl J Med. 1993, 329, S.1456-1462,

13 Okuda S, Nakamura T,Yamamoto T, Rouslahti E, Border WA: Dietary protein restriction rapidly reduces transforming growth factor beta 1 expression in experimental glomerulonephritis. Procl Natl Acad Sci USA . 1991, 88, S.9765-9769, 14 Ohta K, Kim S, Hamaguchi A, Yukimura T, Miura K, Takaori K, Iwao H: Role of angiotensin II in extracellular matrix and transforming growth factor beta 1 expression in hypertensive rats. Eur J Pharmacol . 1994, 269, S.115-119, 15 Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature. 1992, 360, S.361-364, 16 Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppresion of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature. 1990, 346, S.371-374, 17 Border WA, Ruoslathi E: Transforming growth factor beta in disease: the dark side of tisue repair. J Clin Invest. 1992, 90, S.01. Jul, 18 Noble NA, Border WA: Angiotensin II in renal fibrosis: Should TGF-beta rather than blood pressure be the therapeutic target?. Semin Nephrol. 1997, 17, S.455-466, 19 Reyes AA, Karl I, Klahr S: Role of arginine in health and in renal disease. Am J Physiol. 1994, 267, S.F331-F346, 20 Barbul A: Arginine: biochemistry, physiology an therapeutic implications. J Parenter Enteral Nutr. 1986, 10, S.227-238, 21 Furchgott RF, Zawadzki JV: the obligatory role of endothelial cells in the relaxation of arterial smooth muscle cells by acetylcholin. Nature. 1980, 288, S.373-376, 22 Ignarro LJ, Buga GM, Wood KS, Byrne RE, Chaudhuri G: Endothelium-derived relaxing factor produced from artery and vein is nitric oxide. Proc Nat acad Sci. 1987, 84, S.9265-9269,

23 Palmer RMJ, Ferrige AJ, Moncada S: Nitric oxide releases accounts for the biological activity of endothelium derived relaxing factor. Nature. 1987, 327, S.524-526,

24 Castillo L, Sanchez M, Vogt J, Chapman TE, DeRojas Walker TC, Tannenbaum SR, Ajami AM, young VR: Plasma arginine, citrulline and ornithine kinetics in adults with observation on nitric oxide synthesis. Am J Physiol. 1995, 268, S.E360-E367, 25 Kone BS, Baylis C: Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Am J Physiol. 1997, 272, S.F561-F578, 26 Moncada S: Nitric oxide in the vasculature: physiology and pathophysiology. Ann NY Acad Sci. 1997, 811, S.60-67, 27 Bachmann S, Mudel P: Nitric oxide in the kidney: synthesis, localization and function. Am J Kid Dis. 1994, 24, S.112-129, 28 Beckmann JS, Koppenol WH: Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. Am J Physiol. 1996, 271, S.C1424-C1437, 29 Sandau K, Pfeilschifter J, Brune B: Nitric oxide and superoxide induced p53 and Bax accumulation during mesangial cell apoptosis. Kid Int. 1997, 52, S.378-386, 30 Knowle RG, Moncada S: Nitric oxide synthases in mammals. Biochem J . 1994, 298, S.249-258, 31 Nathan C, Xie QW: Regulation of biosynthesis of nitric oxide. J Biol Chem. 1994, 269, S.13725-13728, 32 Hibbs JB Jr, Taintor RR, Vavrin Z: Macrophage cytotoxicity: role for deaminase and iminonitrogen oxidation to nitrate. Science. 1987, 235, S.473-476, 33 Hibbs JB Jr, Taintor RR, Vavrin Z, Rachlin EM: Nitric oxide a cytotoxic activated macrophageeffector molecule. Biochem Biophys Res Comm. 1988, 157, S.87-94, 34 Pfeilschifter J, Eberhardt W, Hummel R, Kunz D, Muhl H, Nitsch D, Pluss C, Walker G: Therapeutic strategies für the inhibition of inducible nitric oxide-synthase - Potential for a novel class of anti-inflammatory agents. Cell Biol Int. 1996, 20, S.51-58,

35 Peters H, Border WA, Noble NA: L-arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. Kid Int. 1999, 55, S.2264-273,

36 Peters H, Noble NA: dietary L-arginine in renal disease. Sem Nephrol. 1996, 16 No. 6, S.567-575, 37 Noris M, Remuzzi G: Physiology and Pathophysiology of nitric oxide in chronic renal disease. Proc Assoc Am Physicians. 1999, 111, S.602-610, 38 Kone BC: Nitric oxide in renal health and disease. Am J Kid Dis. 1997, 30, S.311-333, 41 Forstermann U, Closs EI, Pollock JS, nakane M, Schwar P, Gath I, Kleinert H: Nitric oxide synthase isozymes. Characterization, purification, molecular cloning and functions. Hypertension. 1994, 23, S.1121-1131, 43 Trachtmann H, Futterweit S, Singhal P: Nitric oxide modulates the synthesis of extracellulär matrix proteins in cultured rat mesangial cells. Biochem Biophys Res Commun. 1995, 207, S.120-125, 44 Trachtmann H, Futterweit S, Garg P, Reddy K, Singhal P: Nitric oxide stimulates the activity of a 72-kDa neutral matrix metalloproteinase in cultured rat mesangial cells. Biochem Biophys Res Commun. 1996, 218, S.704-708, 45 Craven PA, Studer RK, Felder J, Phillips S, DeRubertis FR: Nitric oxide inhibition of transfoorming grwoth factor-beta and collagen sythesis in mesangial cells. Diabetes. 1997, 46, S.671-681, 46 Shultz PJ, Schorer AE, Raij L: Effects of endothelium-derived relaxing factor and nitric oxide on rat mesangial cells. Am J Physiol. 1990, 258, S.F162-F167, 47 Hogan M, Cerami A, Bucala R: Advanced glycolisation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest. 1992, 90, S.1110-1115, 50 Bagchus WM, Hoedemaker PJ, Rozing J, Bakker WW: Glomerulonephritis induced by monoclonal Anti-thy-1.1antibodies. Lab Invest. 1986, 55, S.680-687,

51 Narita I, Border WA, Ketteler M, Noble NA: Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest. 1995, 72, S.17-24,

52 Schlondorff D, Nelson PJ, Luckow B, Banas B: Chemokines and renal disease. Kidney Int. 1997, 51, S.610-621, 53 Floege J, Grone HJ: Progression of renal failure: What is the role of Zytokines. Nephrol Dial Transplant. 1995, 10, S.1575-1586, 54 Peters H, Border WA, Noble NA: Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. Kidney Int. 2000, 57, S.922-1001, 55 Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP: Plasminogen activator inhibitor type 1 is a potential target in renal fibrosis. Kidney Int. 2000, 58, S.1841-1850, 56 Tierschutzgesetz vom 02.09.1975. Band BGBI. 2002 S.2313-2610 Ref. Type: Patent, 57 Tierschutzgesetz in der Fassung vom 17.02.1993. Band BGB1. 1993 S.254 zuletzt geändert durch Artikel 86 des EWR-Ausführungsgesetzes vom 27.04.1993 BGB II S. 512 Ref. Type: Patent, 58 Feelisch M : The use of nitric oxide donors in pharmacological studies. Nauyn Schmiedebergs Arch Pharmacol. 1998, 358, S.113-122 , 59 Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest. 1992, 90, S.278-281, 61 van den Meiracker A, van der Linde N, Broere A, Derkx F, Boomsma F: Effects of L-Arginine and L-NAME on the renal function in hypertensive and normotensive subjects. Nephron. 2002, 91, S.444-451, 62 Benigni A, Zoija C, Norris M et al: Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. Am J Kidney Dis. 1999, 33, S.746-753,

63 Rangan GK, Wang Y, Harris DC: Pharmacologic modulators of nitric oxide exacerbate tubulointerstitial inflammation in proteinuric rats. J Am Soc Nephrol. 2001, 12, S.1696-1705,

64 Attia DM, Ni ZN, Boer P et al.: Proteinuria is preceeded by decreased nitric oxide synthesis and prevented by a NO donor in cholesterol-fed rats. Kidney Int. 2002, 61, S.1776-1787, 65 Peters H, Noble NA, Border WA: Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int. 1998, 54, S.1575-1583, 66 Vodovotz Y, Kwon NS, Pospischil M, Manning J, Paik J, Nathan C: Inactivation of nitric oxide synthase after prolonged incubation of mouse macrophages with IFN-gamma and bacterial lipopolysaccharide, J Immunol. 1994, 152 (8), S. 4110-8, 67 Stuehr DJ, Cho HJ, Kwon NS, Weise MF, Nathan CF: Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci U S A. 1991, 88 (17), S. 7773-7777, 68 Rennard SI, Berg R, Martin GR, Foidart JM, Robey PG: Enzyme-linked immunoassay (ELISA) for connective tissue components. Anla Biochem. 1980, 104, S.205-214, 69 Schmidt RJ, Baylis C: Total nitric oxide production is low in patients with chronic renal disease. Kidney Int. 2000, 58, S.1261-1266, 70 Reyes AA, Karl IE, Yates J, Klahr S: Low plasma and renal tissue levels in rats with obstructive nephropathy. Kidney Int. 1994, 45, S.782-787, 71 Baylis C, Vallance P: Measurement of nitrite and nitrate levels in plasma and urine - What does this measure tell us about the activity of the enogenous nitric oxide system?. Curr Opin Nephrol Hypertens. 1998, 7, S.59-62, 72 Chen PY, Sanders PW: L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest. 1991, 88, S.1559-1567, 73 Shihab FS, Yi H, Bennet WM, Andoh TF: Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int. 2000, 58, S.1174-1185,

74 Ribeiro MO, Antunes E, Muscara MN et al.: Nifedipine prevents renal injury in rats with chronic nitric oxide inhibition. Hypertens. 1995, 26, S.150-155,

75 Wenzel UO, Wolf F, Thaiss F et. al: Renovascular hypertension does not influence repair of glomerular lesions induced by anti-thymocyte glomerulonephritis. Kidney Int. 2000, 58, S.1135-1147, 76 Vandenbossche GM, De Muyunck C, Colardyn F, Remon JP: Light stability of molsidominein infusion fluids. J Pharm Pharmacol. 1993, 45, S.486-488, 77 Mattson DL, Wu F: Nitric oxide synthase activity and isoforms in rat renal vasculatur. Hypertens. 2000, 35, S.337-341, 78 Öztürk H, Aldemir M, Büyükbayram H et al.: The effects of the nitric oxide donor molsidomine prevent warm ischemia-reperfusion injury in the rat renal-A functional and histopathological study. Int Urol Nephrol. 2001, 32, S.601-607, 79 Rangan GK, Wang Y, Harris DC: Pharmacological modulators of nitric oxide exacerbate tubuloinstertial inflammation in proteinuric rats. J Am Soc Nephrol. 2001, 12, S.1696-1705, 80 Nori E, Peresleni T, Miller F, Goligorsky MS: In vivo targeting of inducible NO synthase with oligodesoxynucleotides protects rat kidney against ischemia. J Clin Invest. 1996, 97, S.1377-2383, 81 Vos IH, Joles JA, Schurink M, et al.: Inhibition of inducible nitric oxide synthase improves graft function and reduces tubulointerstitial injury in renal allograft rejection. Eur J Pharmacol. 2000, 391, S.31-38, 82 Noiri E, Peresleni T, Miller F, Goligorsky MS: The role of nitric oxide in the pathogenesis of spontaneus murine autoimmune disease: Increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-Monomethyl-L-Arginine. J Clin Invest. 1996, 97, S.2377-2383,

83 Kashem A, Endoh M, Yano N, et al.: Expression of inducible-NOS in human glomerulonephritis. The possible source is infiltrating monocytes/macrophages. Kidney Int. 1996, 50, S.392-399,

84 Peters H, Border WA, Rückert M et al.: L-Arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis. Kidney Int. 2003, 63, S.1382-1392, 85 Nozik ES, Huang YC, Piantadosi CA: L-Arginine enhances injury in the isolated rappit lung during hypoxia. Respir Physiol. 1995, 100, S.63-74, 86 Neilly PJ, Kirk SJ, Gardiner KR et al.: Manipulation of the L-arginine-nitric oxide pathway in experimental colitis. BR J Surg. 1995, 82, S.1188-1191, 87 Zhang F, Casey RM, Ross ME, Iadecola S: Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. Stroke. 1996, 27, S.317-323, 88 Reyes AA, Porras BH, Chasalow FI, Klahr S: L-Arginine decreases the infiltration of the kidney by macrophages in obstructive nephropathy and puromycin-induced nephrosis. Kidney Int. 1994, 45, S.782-787, 89 Reyes AA, Klahr S: Dietary supplementation of L-arginine ameliorates renal hypertrophy in rats fed a high-protein diet. Proc Soc Exp Biol Med. 1994, 206, S.157-161, 90 Katoh T, Takahashi k, Klahr S, et al.: Dietary supplementation with L-arginine ameliorates glomerular hypertension in rats with subtotal nephrectomy. J Am Soc Nephrol. 1994, 4, S.1690-1694, 91 Wu G, Meininger CJ: Arginine nutrition and cardiovascular function. J Nutr. 2000, 130, S.2626-2629, 92 De Nicolal, Bellizzi V, Minutolo R, et al.: Randomized, double-blind, placebo-controlled study of arginine supplementation in chronic renal failure. Kidney Int. 1999, 56, S.674-684, 93 Eisenberger: Abstract. J Am Soc Nephrol. 1999, 10, S.727-728A, 94 Ketteler M, Ikegaya N, Brees DK, Border WA, Noble NA: L-arginine metabolism in immune-mediated glomerulonephritis in the rat. Am J Kidney Dis. 1996, 28, S.878-887,

95 Narita I, Border WA, Ketteler M, Ruoslahti E, Noble NA: L-arginine may mediate the therapeutic effects of low protein diets. Proc Natl Acad Sci USA. 1995, 92, S.4552-4556,

96 Yamamoto T, Noble NA, Miller DE, Border WA: Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int. 1994, 45, S.916-927, 97 Benigni A, Perico N, Remuzzi G: Enothelin antagonists and renal protection. J Cardiovasc Pharmacol. 2000, 35, S.75-78, 98 Sporn MB, Roberts AB: A major advance in the use of growth factors to enhance wound healing. J Clin Invest. 1993, 92, S.2565-2566, 99 Romberger DJ: Fibronectin. Int J Biochem Cell Biol. 1997, 29, S.939-943, 100 Baricos WH, Cortez SL, El-Dahr SS, Schnaper HW: ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MM-2 cascade. Kidney Int. 1995, 47, S.664-671, 101 Eitzman DT, McCoy RC, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH: Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest. 1996, 97, S.232-237, 102 Yamamoto T, Mundy CA, Wilson CB: Quantitative and qualitative studies of antibody induced mesangial cell damage in the rat. Kidney Int. 1987, 32, S.514-525, 103 Eberhadt W, Beeg T, Beck KF et al.: Nitric oxide modulates expression of metalloproteinase-9 in rat mesangial cells. Kidney INt. 2000, 57, S.59-69, 104 Arnal FJ, Warin L, Miche JB: Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest. 1992, 90, S.647-652, 105 Frei U, Schober-Halstenberg HJ: Nierenersatztherapie in Deutschland. Band QuaSi-Niere Jahresbericht 2001/2002.
Berlin
, 106 United States Renal Data Systems: Annual Data Report 2003.
Minneapolis, USA
, 107 Green LC, Wagner DA, Glogowki J et al.: Analysis of nitrate, nitrite and 15N-nitrate in biological fluids. Anal Biochem. 1982, 126, S.131-138,

108 Watanabe N, Kamei S, Ohikubo A et al.: Urinary protein as measured with a pyrogallol-molybdate complex, manually and in a Hitachi 726 automatic analyzer. Clin Chem. 1986, 32, S.1551-1554,

109 Watanabe G, Tomiyama H, Doba N: Effects of oral administration of L-arginine on renal function in patients with heart failure. J Hypertens. 2000, 18, S.229-234, 110 Maxwell AJ, Cooke JP: Cardiovascular effects of L-arginine. Curr Opin Nephrol Hypertens. 1998, 7, S.63-70, 11 1 Sigmon DH, Gonzales-Feldman E, Cavasin MA, Potter DL, Beierwal WH: Role of nitric oxide in the renal hemodynamic response to unilateral nephropathy. J Am Soc Nephrol. 2004, 15(6), S.1413-1420, 11 2 Six I, Van Belle E, Bordet R, Corseaux D, Callebert J, Dupuis B, Bauters C, Bertrand ME: L-Arginine and L-NAME have no effects on the reendotheliazation process after arterial balloon injury. Cardiovascular Research. 1999, 43, S.731-738, 113 Ashab I, Peer G, Blum M et al.: Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int. 1995, 47, S.1515-1521, 114 Krumenacker JS, Hanafy KA, Murad F: Regulation of nitric oxide and soluble guanylyl cyclase. Brain Res Bull. 2004, 62 (6), S. 505-15, 115 Marletta, MA: Nitric oxide synthase structure and mechanism. J Biol Chem. 1993, 268, S. 12231- 12234, 116 Murad, F: Cellular signaling with nitric oxide and cyclic GMP. Braz J Med Biol Res. 1999, 32 (11), S. 1317-1327, 117 Nathan C, Xie QW: Regulation of biosynthesis of nitric oxide. J Biol Chem. 1994, 269, S. 13725- 13728, 118 Malinski T, Taha Z: Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor. Nature. 1992, 358 (6388), S. 676-678,

119 Sandau KB, Brune B: Molecular actions of nitric oxide in mesangial cells. Histol Histopathol. 2000, 15 (4), S. 1151-1158,

120 Murad F: The excitement and rewards of research with our discovery of some of the biological effects of nitric oxide. Circ Res. 2003, 92 (4), S. 339-341, 121 Radi R, Beckman JS, Bush KM, Freeman BA: Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem. 1991, 266 (7), S. 4244-4250, 122 Lowenstein CJ, Dinerman JL, Snyder SH: Nitric oxide: A physiologic messenger. Ann Intern Med. 1994; 120 (3), S. 227-237